Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.55 -0.02 (-0.12%) 4:48 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.55 -0.02 (-0.12%) 4:48 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Hims & Hers Health (HIMS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
by Zacks Equity Research
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?
by Zacks Equity Research
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Henry Schein (HSIC) Extends Partnership With Special Olympics
by Zacks Equity Research
Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
by Zacks Equity Research
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
Teleflex (TFX) Expands Vascular Access Portfolio With New Launch
by Zacks Equity Research
Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down
by Zacks Equity Research
Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.
National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.
Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stock to Buy for May 8th
by Zacks Equity Research
HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.
New Strong Buy Stocks for May 8th
by Zacks Equity Research
BRFS, GPS, GTN, HIMS and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2024.
Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 150% and 2.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Brokers Suggest Investing in Hims & Hers Health (HIMS): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Hims & Hers Health (HIMS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.